Mobile

A randomized phase 3 study of two doses of ALIMTA in patients with locally advanced or metastatic Non-Small Cell Lung Cancer who have failed a prior platinum-containing chemotherapy

Mise à jour : Il y a 4 ans
Référence : EUCTR2004-000815-25

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The primary objective of this study is to compare overall survival time following treatment with ALIMTA 500 mg/m2 versus ALIMTA 900 mg/m2 in patients with locally advanced or metastatic (Stage III or IV) NSCLC who have failed a prior platinum-containing chemotherapy.

Critère d'inclusion

  • Patients with locally advanced or metastatic Non-Smal Cell Lung Cancer who have failed a prior Platinum-containing chemotherapy

Liens